KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Operations: 2010-2025

Historic Cash from Operations for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $999,000.

  • TherapeuticsMD's Cash from Operations rose 1507.04% to $999,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 155.06%. This contributed to the annual value of $1.2 million for FY2024, which is 105.07% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's Cash from Operations is $999,000, which was up 162.20% from $381,000 recorded in Q2 2025.
  • TherapeuticsMD's Cash from Operations' 5-year high stood at $48.0 million during Q4 2021, with a 5-year trough of -$38.4 million in Q1 2021.
  • Its 3-year average for Cash from Operations is -$1.8 million, with a median of -$71,000 in 2024.
  • As far as peak fluctuations go, TherapeuticsMD's Cash from Operations crashed by 134.03% in 2023, and later surged by 1,507.04% in 2025.
  • Quarterly analysis of 5 years shows TherapeuticsMD's Cash from Operations stood at $48.0 million in 2021, then slumped by 37.01% to $30.2 million in 2022, then plummeted by 116.40% to -$5.0 million in 2023, then spiked by 100.34% to $17,000 in 2024, then spiked by 1,507.04% to $999,000 in 2025.
  • Its Cash from Operations was $999,000 in Q3 2025, compared to $381,000 in Q2 2025 and $699,000 in Q1 2025.